Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1382

1.

Progressive multifocal leukoencephalopathy therapy.

Clifford DB.

J Neurovirol. 2014 Sep 17. [Epub ahead of print]

PMID:
25227934
[PubMed - as supplied by publisher]
2.

Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study.

Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.

Eur Neurol. 2014 Sep 6;72(3-4):173-180. [Epub ahead of print]

PMID:
25226868
[PubMed - as supplied by publisher]
3.

Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells, and Treatment Algorithms for Inflammatory Bowel Diseases.

Danese S, Panés J.

Gastroenterology. 2014 Sep 11. pii: S0016-5085(14)01087-7. doi: 10.1053/j.gastro.2014.08.044. [Epub ahead of print] Review.

PMID:
25220794
[PubMed - as supplied by publisher]
4.

Update on Disease-Modifying Treatments for Multiple Sclerosis.

Carrithers MD.

Clin Ther. 2014 Sep 10. pii: S0149-2918(14)00537-2. doi: 10.1016/j.clinthera.2014.08.006. [Epub ahead of print] Review.

PMID:
25218310
[PubMed - as supplied by publisher]
5.

▼Dimethyl fumarate for relapsing-remitting multiple sclerosis.

[No authors listed]

Drug Ther Bull. 2014 Sep;52(9):105-8. doi: 10.1136/dtb.2014.9.0279.

PMID:
25213591
[PubMed - in process]
6.

MRI pattern in asymptomatic natalizumab-associated PML.

Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.

J Neurol Neurosurg Psychiatry. 2014 Sep 9. pii: jnnp-2014-308630. doi: 10.1136/jnnp-2014-308630. [Epub ahead of print]

PMID:
25205744
[PubMed - as supplied by publisher]
7.

Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort.

Carvalho AT, Abreu P, Sá MJ.

Acta Med Port. 2014 Jul-Aug;27(4):437-43. Epub 2014 Aug 29.

PMID:
25203951
[PubMed - in process]
Free Article
8.

[Regarding the article: "multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort"].

de Sá J.

Acta Med Port. 2014 Jul-Aug;27(4):409-10. Epub 2014 Aug 29. Portuguese. No abstract available.

PMID:
25203944
[PubMed - in process]
Free Article
9.

Multiple sclerosis disease modifying medicine utilisation in Australia.

Hollingworth S, Walker K, Page A, Eadie M.

J Clin Neurosci. 2014 Sep 3. pii: S0967-5868(14)00458-5. doi: 10.1016/j.jocn.2014.05.034. [Epub ahead of print] Review.

PMID:
25194821
[PubMed - as supplied by publisher]
10.

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).

Fernandez O, Alvarez-Cermeno JC, Arnal-Garcia C, Arroyo-Gonzalez R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Prieto JM, Ramio-Torrenta L, Romero-Pinel L, Saiz A, Rodriguez-Antiguedad A, Grupo Post-Ectrims GP.

Rev Neurol. 2014 Sep 16;59(6):269-280. Spanish, English.

PMID:
25190340
[PubMed - as supplied by publisher]
Free Article
11.

Reversible hyporegenerative anemia during natalizumab treatment.

Monteleone F, Buccisano F, Boffa L, Buttari F, Di Veroli A, Borriello G, Rossi S, Centonze D.

Mult Scler. 2014 Sep 3. pii: 1352458514546516. [Epub ahead of print] No abstract available.

PMID:
25186208
[PubMed - as supplied by publisher]
12.

The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.

Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA.

JAMA Neurol. 2014 Sep 1. doi: 10.1001/jamaneurol.2014.1895. [Epub ahead of print]

PMID:
25178496
[PubMed - as supplied by publisher]
13.

Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice.

Conway DS, Cohen JA.

Mult Scler. 2014 Sep;20(10):1280-1. doi: 10.1177/1352458514535283. No abstract available.

PMID:
25160120
[PubMed - in process]
14.

Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study.

Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K.

Mult Scler. 2014 Aug 26. pii: 1352458514546790. [Epub ahead of print]

PMID:
25159275
[PubMed - as supplied by publisher]
15.

Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab.

Beume LA, Dersch R, Fuhrer H, Stich O, Rauer S, Niesen WD.

J Clin Neurosci. 2014 Aug 20. pii: S0967-5868(14)00361-0. doi: 10.1016/j.jocn.2014.05.028. [Epub ahead of print]

PMID:
25150761
[PubMed - as supplied by publisher]
16.

Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.

Muris AH, Rolf L, Damoiseaux J, Koeman E, Hupperts R.

BMC Neurol. 2014 Aug 20;14(1):164. doi: 10.1186/s12883-014-0164-5.

PMID:
25138918
[PubMed - in process]
Free Article
17.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

[No authors listed]

Neurology. 2014 Aug 19;83(8):773. doi: 10.1212/WNL.0000000000000766. No abstract available.

PMID:
25135914
[PubMed - in process]
18.

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.

Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H.

J Exp Med. 2014 Aug 25;211(9):1833-46. doi: 10.1084/jem.20140540. Epub 2014 Aug 18.

PMID:
25135296
[PubMed - in process]
19.

Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.

Galuppo M, Giacoppo S, Sessa E, Bramanti P, Mazzon E.

J Neurol Sci. 2014 Jul 30. pii: S0022-510X(14)00491-2. doi: 10.1016/j.jns.2014.07.045. [Epub ahead of print]

PMID:
25115502
[PubMed - as supplied by publisher]
20.

The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up study.

van Rossum JA, Vennegoor A, Killestein J.

Mult Scler. 2014 Aug 11. pii: 1352458514543341. [Epub ahead of print] No abstract available.

PMID:
25112817
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk